Yoon Sim Yap on Muck Rack

Yoon Sim Yap

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yoon Sim

Contact Yoon Sim, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A multi-ancestry genome-wide study of tamoxifen metabolism and breast cancer recurrence

|
By Chiea Chuen Khor, Whee Sze Ong, Elaine Hsuen Lim, Etienne Chatelut, Sylvia Chen, Jean Abraham, Natalia Sutiman, Sze Lee, Zheng Li, Kar Seng Sim, Diana M Eccles, William J. Tapper, Tom C Maishman, Stefan Winter Verified, Leila Dorling, Qi Guo, Carlos Caldas, Helena Earl, Louise Hiller, Janet Dunn, Yoon Sim Yap, Mabel Siu‐Chun Wong, Fuh Yong Wong, Rebecca Dent, Arafat Tfayli, Elke Schaeffeler, Ute Hamann, Matthias W. Beckmann, Florence Dalenc, Melanie White-Koning, Hiltrud Brauch, Werner Schroth, Wilfried Renner, Matthias Schwab, Fabienne Thomas, Balram Chowbay, Thomas E. Muerdter, Cecile Arellano, Nathalie K. Zgheib, Boian Ganchev, Peter Krippl, Uwe Langsenlehner, Tanja Langsenlehner, Michel Eichelbaum
| Nature Verified
Abstract Tamoxifen’s pharmacokinetics are strongly influenced by the highly polymorphic CYP2D6, while the influence of other genetic variants has been inconclusive. To further delineate this genotypic-phenotypic impact, we conducted a multi-ancestry genome-wide association study in 636 hormone-receptor-positive (HR+) breast cancer (BC) patients treated with 20 mg tamoxifen daily for ≥8 weeks and validated these genetic determinants in another 869 patients.
Open in Who Shared Issue with article?

Comprehensive benchmarking of methods for mutation calling in circulating tumor DNA - Nature Communications

|
By Hanaé Carrié, Yi Ting Lau, Polly Poon, Iain Beehuat Tan, Yoon Sim Yap, Limsoon Wong, Kiran Krishnamachari
| Nature Verified
Abstract Detection of somatic mutations in cell-free DNA (cfDNA) is challenging due to low variant allele frequencies and extensive DNA degradation. Here we develop a benchmarking strategy using longitudinal patient-matched cfDNA samples from individuals with colorectal and breast cancer.
Open in Who Shared Issue with article?

A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer - npj Breast Cancer

|
By Emi Noguchi, Yen-Shen Lu, Koji Matsumoto, Yoshiko Umeyama, Yuki Kojima, Tomomi Hata, Yasuhiro Fujiwara, Yoon Sim Yap
| Nature Verified
Abstract Palbociclib combined with endocrine therapy is approved for treating patients with hormone-receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer; however, data on palbociclib combined with tamoxifen are limited. We investigated the efficacy and safety of palbociclib–tamoxifen in patients with HR+/HER2− advanced breast cancer.
Open in Who Shared Issue with article?
See all 3 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified